ATE180261T1 - Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen - Google Patents

Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Info

Publication number
ATE180261T1
ATE180261T1 AT91903010T AT91903010T ATE180261T1 AT E180261 T1 ATE180261 T1 AT E180261T1 AT 91903010 T AT91903010 T AT 91903010T AT 91903010 T AT91903010 T AT 91903010T AT E180261 T1 ATE180261 T1 AT E180261T1
Authority
AT
Austria
Prior art keywords
proteins
pharmaceutical
human lymphocytes
dna coding
biological uses
Prior art date
Application number
AT91903010T
Other languages
English (en)
Inventor
Thierry Hercend
Frederic Triebel
Original Assignee
Inst Nat Sante Rech Med
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Roussy Inst Gustave filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE180261T1 publication Critical patent/ATE180261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91903010T 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen ATE180261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9000126A FR2656800B1 (fr) 1990-01-08 1990-01-08 Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.

Publications (1)

Publication Number Publication Date
ATE180261T1 true ATE180261T1 (de) 1999-06-15

Family

ID=9392569

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91903010T ATE180261T1 (de) 1990-01-08 1991-01-08 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Country Status (13)

Country Link
US (2) US5773578A (de)
EP (1) EP0510079B1 (de)
JP (1) JP2997053B2 (de)
AT (1) ATE180261T1 (de)
DE (1) DE69131249T2 (de)
DK (1) DK0510079T3 (de)
ES (1) ES2134770T3 (de)
FR (1) FR2656800B1 (de)
GR (1) GR3030811T3 (de)
IL (1) IL96907A (de)
MX (1) MX9203379A (de)
WO (1) WO1991010682A1 (de)
ZA (1) ZA91134B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
AU755030B2 (en) * 1994-05-06 2002-11-28 Institut Gustave Roussy LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
ATE227586T1 (de) 1995-07-21 2002-11-15 Applied Research Systems Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein
IL130168A (en) * 1996-11-29 2006-09-05 Serono Lab Genetically engineered cells containing LAG-3-expressing DNA and their use
EP0900841A1 (de) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Spleissvarianten von LAG-3
EP0893507A1 (de) 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
WO2000037639A2 (en) * 1998-12-18 2000-06-29 Incyte Pharmaceuticals, Inc. Lymphocytic membrane proteins
SE0103423D0 (sv) * 2001-10-12 2001-10-12 Astrazeneca Ab Polymorphism
CA2476518A1 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2004217526B2 (en) 2003-02-28 2010-02-04 St. Jude Children's Research Hospital Inc. T cell regulation
KR100808925B1 (ko) 2006-09-29 2008-03-03 고려대학교 산학협력단 돼지 ｌａｇ-3 융합 이뮤노글로블린
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3508502B1 (de) 2013-09-20 2023-04-26 Bristol-Myers Squibb Company Kombination aus anti-lag-3-antikörpern und anti-pd-1-antikörpern zur behandlung von tumoren
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3116909B1 (de) 2014-03-14 2019-11-13 Novartis Ag Antikörpermoleküle gegen lag-3 und verwendungen davon
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN106999577B (zh) 2014-07-16 2021-12-21 特兰斯吉恩股份有限公司 溶瘤病毒和免疫检查点调节因子组合
US10555981B2 (en) 2014-07-16 2020-02-11 Transgene S.A. Oncolytic virus for expression of immune checkpoint modulators
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
RU2018123481A (ru) 2015-12-16 2020-01-20 Мерк Шарп И Доум Корп. Анти-lag3 антитела и антигенсвязывающие фрагменты
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
KR20190137911A (ko) 2017-04-21 2019-12-11 신라젠(주) 항암 백시니아 바이러스와 관문 저해제 병용 요법
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
US20220193198A1 (en) 2019-03-29 2022-06-23 Institut Curie Interleukin-2 Variants with Modified Biological Activity
BR112021021713A2 (pt) 2019-05-13 2022-04-19 Regeneron Pharma Método de tratamento de câncer ou inibição do crescimento de um tumor
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
EP3824954A1 (de) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
CA3182333A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
EP4229090A1 (de) 2020-10-16 2023-08-23 Université d'Aix-Marseille Anti-gpc4-einzeldomänenantikörper
CA3196243A1 (en) 2020-10-20 2022-04-28 Angela Marinetti Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
JP2023550402A (ja) 2020-11-18 2023-12-01 アンスティテュ・クリー ビグアニジンの二量体及びその治療的使用
IL304031A (en) 2021-01-14 2023-08-01 Inst Curie Variants of single-domain HER2 antibodies and their chimeric antigenic receptors
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
EP4380682A1 (de) 2021-08-05 2024-06-12 Institut Curie Dynamische abtastvorrichtung zur ministrahlerzeugung
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023180552A1 (en) 2022-03-24 2023-09-28 Institut Curie Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023194607A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023194608A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
WO2024068617A1 (en) 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers

Also Published As

Publication number Publication date
GR3030811T3 (en) 1999-11-30
ZA91134B (en) 1992-08-26
DK0510079T3 (da) 1999-11-29
EP0510079B1 (de) 1999-05-19
US5874250A (en) 1999-02-23
JPH05503520A (ja) 1993-06-10
IL96907A (en) 1998-10-30
EP0510079A1 (de) 1992-10-28
DE69131249D1 (de) 1999-06-24
WO1991010682A1 (fr) 1991-07-25
DE69131249T2 (de) 1999-12-30
FR2656800A1 (fr) 1991-07-12
IL96907A0 (en) 1992-03-29
ES2134770T3 (es) 1999-10-16
JP2997053B2 (ja) 2000-01-11
FR2656800B1 (fr) 1992-05-15
US5773578A (en) 1998-06-30
MX9203379A (es) 1992-09-01

Similar Documents

Publication Publication Date Title
ATE180261T1 (de) Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen
ES2142953T3 (es) Factor de crecimiento y diferenciacion de la familia del tgf-beta.
DE69016426D1 (de) Biologische klappenprothese.
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
AU3310595A (en) Compositions and methods for identifying biologically active molecules
NO971875L (no) Cathepsin 02 protease
FR2661187B1 (fr) Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
DE69728897D1 (de) Saeugetierchemokine
DE69836333D1 (de) Neisseria lactoferrin-bindendes protein
ATE278781T1 (de) Tioredioxine h aus zwig und hart-weizen und ähnliche proteine, diese kodierende dna-fragmente und verfahren zu ihrer herstellung
DE68912536D1 (de) Flüssiges Nahrungsmittel zur Proteinzuführung.
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
PT676413E (pt) Proteina de ligacao a interferoes alfa/beta, sua preparacao e utilizacao
AU4981093A (en) Nucleotide sequences coding for cryptosporidium proteins, polypeptides coded by said sequences and kits for the use thereof
FI880412A (fi) Biologisk respons modifierande aemne.
TR26931A (tr) Lak koagülasyonunda molipten bilesiklerinin kullanilmasi.
NO905496D0 (no) Biologisk forenelige, stoff-spesifikke reagenser til behandling av fysiologiske vaesker.
EP0780472A3 (de) Stress Proteine
DE3880486D1 (de) Aspirator zur aufnahme von koerperfluessigkeiten.
FI885025A (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE59611293D1 (de) Protein mit dnase-aktivität
RU95114858A (ru) Новый пептидный фрагмент, обладающий биологической активностью инсулина
DE69033553T2 (de) Rekombinante herstellung von laktoperoxidase
ITRM980790A0 (it) Dna copia (cdna) che codifica per una proteina con l'attivita' biologi ca dell'euserratina 4, procedimento per la sua preparazione, suoi usi
IT1270614B (it) Proteine ad attivita' antitumorale da organi di mammiferi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee